CEOs from Medtronic, Intuitive Surgical, Boston Scientific and Dexcom were on hand this week in San Francisco to discuss the year ahead at the J.P. Morgan Healthcare Conference.

The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

BD invested $10 million last year to increase manufacturing capacity. The recent expansion has created more than 200 jobs.

Retractable Technologies, Inc. (NYSA: RVP) recently made headlines by withdrawing its complaint in the United States Court of International Trade on January 8, 2025. The company issued a press release ...

Veterinary toxicologists are warning clients about the dangers of accidental exposure to semaglutide weight loss medications ...

Administering your pet's medication can often be challenging, especially when it involves an injection. Since the introduction of Ozempic® and other semaglutide weight-loss medications, however, there ...

Glucagon prescriptions for severe hypoglycemia rose in Medicaid beneficiaries with the introduction of newer products but likely met only a fraction of the high-risk population’s needs.

Argentina Diabetes Devices Market To Reach US$ 1,031.89 Million By 2033, Growing At A CAGR Of 7.48% Astute Analytica ...